ESSA Pharma Inc.
EPIX · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.13 | 0.10 | -0.07 | 0.85 |
| FCF Yield | -5.57% | -9.77% | -8.15% | -1.25% |
| EV / EBITDA | 2.11 | 2.50 | 1.60 | -26.13 |
| Quality | ||||
| ROIC | -4.59% | -6.48% | -8.13% | -6.15% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 1.05 | 1.07 | 0.76 | 0.53 |
| Growth | ||||
| Revenue 3-Year CAGR | 513,846.06% | 513,846.06% | 513,846.06% | 513,846.06% |
| Free Cash Flow Growth | 38.67% | -5.85% | -92.21% | 41.41% |
| Safety | ||||
| Net Debt / EBITDA | 17.26 | 13.55 | 10.93 | 16.33 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -5,336.56 | -3,235.19 | -7,055.71 | -3,078.85 |